Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 20.6% – Still a Buy?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT)’s share price rose 20.6% on Wednesday . The stock traded as high as $2.88 and last traded at $2.81. Approximately 51,176 shares were traded during mid-day trading, an increase of 206% from the average daily volume of 16,703 shares. The stock had previously closed at $2.33.

Alaunos Therapeutics Trading Up 20.6 %

The company’s 50-day moving average price is $2.44 and its 200-day moving average price is $4.77.

Hedge Funds Weigh In On Alaunos Therapeutics

An institutional investor recently bought a new position in Alaunos Therapeutics stock. Virtu Financial LLC purchased a new stake in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 15,440 shares of the company’s stock, valued at approximately $28,000. Virtu Financial LLC owned 0.10% of Alaunos Therapeutics at the end of the most recent reporting period. 27.72% of the stock is owned by institutional investors.

About Alaunos Therapeutics

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.